Berkeley Lights- Biotech-Wert in ARK ETF enthalten

Der Wert hat sich in 2020 nach dem IPO an der Nasdaq auf über 100 Dollar verdoppelt um im ersten Quartal 2021 auf knapp unter 40 Dollar einzubrechen. Aktuell um 40 Dollar notierend wurde womöglich ein charttechnischer Boden gefunden.
Anfang April wurde Berkely nun in die ARK Investment Fonds von Cathy Wood aufgenommen.
Hier könnte ein sehr gutes Chance- Risiko Potenzial vorliegen.  

Hier ist Berkeley inzwischen enthalten:
www.ark-funds.com/arkg

Der Kurs von Berkeley schwankt seit Anfang März 2021 um 50 Dollar/ 40 Euro, nicht um 40 Dollar, wie irrtümlich oben geschrieben. Die niedrigste Notierung lag Ende März bei 42 Dollar/ 36 Euro.

Letzte News:
EMERYVILLE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Today, Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, announced the launch of Opto Assure, a series of assays that provides yield and product quality data at an earlier stage in cell line development. The first of the series enables direct detection of product aggregates, ensuring a faster ramp toward volume production by evaluating biotherapeutic protein quality sooner in the antibody therapeutic development process. With Opto Assure, customers can rapidly select clonal cell lines with favorable manufacturability profiles, leading to decreased scale-up costs and better downstream products.

Cell line development has become more challenging with the emergence of complex antibody therapeutic formats. These highly engineered proteins are prone to quality issues including aggregation, by-products, and post-translational modifications, which impact drug manufacturability, shelf life, and safety. Berkeley Lights enhances its technology leadership position in cell line development by going beyond titer assessment in the clone selection process. Opto Assure helps minimize risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality.

“We’re excited to empower manufacturers of complex therapeutics, such as bispecifics, to develop better production cell lines faster. As we build out the Opto Assure series, customers can look forward to added capabilities that further reduce resources spent on preventing product failures downstream and ensure a more efficient process,” said John Proctor, Ph.D., SVP of Antibody Therapeutics at Berkeley Lights.

About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelec chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
 

Berkeley Lights to Report First Quarter 2021 Financial Results on May 11, 2021

EMERYVILLE, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be reporting financial results for the first quarter 2021 before market open on Tuesday, May 11, 2021. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the Company’s website at: www.berkeleylights.com. The webcast will be archived and available for replay after the event.  

Sie bewegt sich in die richtige Richtung, im Ark ETF wurde Berkeley gestern auch noch mal gekauft
So long  

Aber sonst haben offenbar viele Berkeley gerade nicht auf dem Schirm. Dann warten wir mal, ob sich das nach den Zahlen am 11.5. ändert.  

EMERYVILLE, Calif., June 01, 2021 (GLOBE NEWSWIRE)
Today, Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, announced the release of its TechAccess Subscription model to enable broader customer access to their cutting-edge, single-cell screening technology. The new offering brings requested volume and throughput flexibility to customers who want to access the company’s cell line development and antibody discovery workflows. The all-inclusive subscription provides customers with a comprehensive suite of products, including a Beacon system, software, consumables, service, support, and commercial use rights. Each TechAccess subscription has a renewable 1-year term and provides customers with the turnkey capacity they need and the financial benefits of no up-front capital expense. The all-inclusive offering also provides customers with innovation insurance, providing access to Berkeley Lights’ latest technology features and capabilities at no additional cost.

Berkeley Lights has already started signing subscription-based access agreements with customers doing cell line development as well as antibody discovery and expects many more to come. Many customers welcome the capacity-based access model as an alternative to direct purchase of Berkeley Lights technology. Those with lower capacity requirements are particularly eager to take advantage of the significant speed, throughput and quality benefits of the Berkeley Lights platform, under a model that now matches their capacity needs. “We are thrilled that we can now offer this game-changing technology to our partners and customers as part of our core services,” said Amy He, Senior Director of Bionova Scientific Process Development. "We will be able to deliver high-quality product faster while meeting our need for campaign flexibility with no up-front capital expense.

The release of the TechAccess Subscription model aligns with the upcoming availability of the upgraded Opto Plasma B Discovery 4.0 workflow and Opto Assure for cell line development assays. “Our customers have been requesting tailored access to our technology and the TechAccess Subscription model fits their specific needs,” said John Proctor, Ph.D., SVP, Antibody Therapeutics Berkeley Lights. “Since the release, we have seen a positive customer response to this program, which we believe will broaden our served available market and accelerate the adoption of Berkley Lights technology.”

About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelec chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
(...)
Investor Contact: ir@berkeleylights.com  

Das wurde aber auch Zeit  

Die Einladung hat der Ark Investment Fonds gestern gleich zwei Mal für Käufe genutzt.
Ich habe mich drangehängt. Allerdings nur ein  Mal und mit geringerem Volumen :)  

das short- thema könnte sich erledigt haben  

Heute hat der Kurs genau an der Unterstützung gedreht. Bisher ist der Tick hier aber mal richtig daneben gegangen. Der ARK Investment Fonds trifft halt auch nicht immer den richtigen Punkt zum Einstieg  

Kauf zu 8,85
Entweder ich freue mich demnächst darüber oder die Kohle muss ich komplett abschreiben  

Wollen doch mal sehen ob der Abwärtstrend nicht doch mal endet  

Ein Chart sagt mehr als 1000 Worte  

... sich etwa doch noch mal regen? Das sieht ja fast wie eine Bodenbildung aus.  

Berkeley Lights and Aanika BioSciences Reach Strategic Partnership Milestone By Identifying A Commercially Viable Antimicrobial Peptide
07/27/2022

"Using Berkeley Lights' high-throughput, functional screening service, Aanika BioSciences will now rapidly commercialize the propriety peptide to help improve and protect global food system"

https://investors.berkeleylights.com/news/...ial-Peptide/default.aspx


Man darf gespannt sein.  

https://m-de.marketscreener.com/kurs/aktie/...sident-Strate-41166347/

Scheint am Markt ganz gut anzukommen  

Berkeley Lights and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of a Patient-Derived T cell Receptor Sequence Against a Cancer Neoantigen

https://investors.berkeleylights.com/news/...-Neoantigen/default.aspx

Auf so eine Nachricht haben wohl alle Investierten gewartet. Mal sehen was der Markt daraus macht.
 

Freier Fall könnte zu Ende sein  

Finanzielle Situation hat sich verbessert, bleibt aber kritisch.
Newsflow liest  sich gar nicht schlecht:
.
https://investors.phenomex.com/news/news-details/...lows/default.aspx
.
Interessiert den Markt aber bislang auch nicht. Warum auch immer.
 

.. die zumindest können hier nichts mehr verkaufen.
Und jetzt noch short gehen? Hm.

Aktuelle Einschätzung eines Analysten: Ziel 3 Dollar.
.
https://m-de.marketscreener.com/kurs/aktie/...ale-Bewertung-43833647/
.
Würde mir ja fast schon reichen  

Erstaunlich.  

On July 7, 2023, the PhenomeX Inc. (NasdaqGS:CELL) announced that its Board of Directors (Board), with the support of management and legal advisors, has launched a process to explore, review and evaluate a range of potential strategic alternatives focused on addressing capital requirements and maximizing stockholder value. The Board has approved managements engagement of financial and legal advisors.
S&P Capital IQ - 2023